Drug intelligence / Profile preview

ESG-409

Development stage: Preclinical
Lead developer: Shanghai Escugen Biotechnology
Modality: Small Molecules

Overview

ESG-409 is a drug developed by Shanghai Escugen Biotechnology Co., Ltd. It functions as an inhibitor of CD276 (CD276 antigen), a protein involved in immune regulation. The drug is currently in preclinical development for therapeutic areas including neoplasms and respiratory diseases, with a specific active indication for Non-Small Cell Lung Cancer.

Targets

B7-H3

Beyond the preview

Go deeper on ESG-409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESG-409.

Explore the full profile